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Background: Collection of exhaled breath condensate (EBC) is a safe, non-invasive method to
collect droplets of the airway surface liquid and measure mediators of airway inflammation
and oxidative stress, such as cysteinyl-leukotrienes (cys-LTs) and 8-isoprostane.
Objective: The aim of our study was to investigate baseline values of inflammatory lipid medi-
ators in EBC and their relation to asthma severity.
Methods: Nineteen healthy subjects, 16 mild, 12 moderate and 15 severe asthmatics were
studied. All subjects attended a clinic visit for spirometry and EBC collection. The concentra-
tions of exhaled cys-LTs and 8-isoprostane were measured by means of specific enzyme immu-
noassays.
Results: 8-isoprostane levels were significantly increased in mild (49.1  5.2 pg/mL,
p < 0.001), moderate (49.7  5.2 pg/mL, p < 0.001) and severe asthmatics (77.7  7.3 pg/
mL, p < 0.001), compared to healthy controls (16.4  1.6 pg/mL). Moreover, 8-isoprostane
levels were significantly higher in severe compared to mild and moderate asthmatics
(p < 0.01). Cys-LT levels were significantly higher in moderate (34.6  4.4 pg/mL, p < 0.05)
and severe asthmatics (47.9  6.0 pg/mL, p < 0.001), while no significant difference was found
between healthy controls and mild asthmatics. 8-isoprostane levels in EBC of asthmatics
strongly correlated with cys-LT levels (rZ 0.61, p < 0.0001).otriene; EBC, exhaled breath condensate; BAL, bronchoalveolar lavage; FEV1, forced expiratory
oids; BMI, body mass index.
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Exhaled eicosanoids in asthma and their relation to clinical severity 751Conclusions: 8-isoprostane and cys-LT are detectable in EBC of healthy subjects and their
levels progressively increase in asthmatic patients according to disease severity. The correla-
tion found between these two lipid mediators indicating a link between oxidative stress and
airway inflammation.
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Inflammation is the cornerstone of asthma pathophysi-
ology.1 Hence, monitoring airway inflammation may be
useful in the follow up of asthmatic patients and in guiding
pharmacological therapy. Different biomarkers might
reflect the different aspects of lung inflammation or
oxidative stress, which is an important component of
inflammation.2 Quantification of oxidant stress status in
vivo may be very important in assessing airway inflamma-
tion in patients with asthma; however it has not often been
possible due to recognized shortcomings with methods
previously available.3
Eicosanoids, which include prostaglandins (PGs),
leukotrienes (LTs) and thromboxanes, are important
inflammatory mediators of asthma4 that derive via
a cascade pathway from arachidonic acid, a cell
membrane phospholipid constituent. F2-isoprostanes are
PGF2a isomers produced in situ in membrane phospho-
lipids, primarily by free radical-induced peroxidation of
arachidonic acid in vivo.5 Particular attention has focused
on 8-isoprostane, which is among the most abundant of
the F2-isoprostanes and has several biological effects.6
Due to its stability, specificity for lipid peroxidation, in
vivo production, and relative abundance in biological
fluids, it is a reliable marker of lipid peroxidation and
oxidative stress.
Cysteinyl-leukotrienes (cys-LTs; LTC4/D4/E4) are also
eicosanoids derived from arachidonic acid, via the lip-
oxygenase enzymatic pathway. Their synthesis is primarily
dependent on arachidonic acid release by phospholipases
and activation of 5-lipoxygenase.7 All cys-LTs have the same
range of biological effects, with LTE4 being 10-fold less
potent than LTD4.8 Cys-LTs are generated predominantly by
mast cells and eosinophils and have been implicated in the
pathophysiology of asthma.9
Most of the studies investigating the role of eicosanoids
in asthma have either used invasive techniques, such as
bronchoalveolar lavage,10 or have measured them in
plasma11 or urine,12 far from the site of production.
Exhaled breath condensate (EBC) consists mainly of
condensed water vapor. Only a small fraction of it concerns
aerosolized respiratory fluid droplets, which are released
from the respiratory epithelial lining fluid and contain
traces of non-volatile solutes,13 such as eicosanoids. These
solutes can be recovered in EBC samples. EBC collection
does not affect the airway in contrast to bronchial biopsy,
bronchoalveolar lavage and induced sputum. It can be
obtained with minimal risk and minimal inconvenience for
both adults and children, especially in patients with severe
asthma, where relative contra-indications exist for more
invasive techniques. EBC is, therefore, a simple non-inva-
sive technique that may be used to sample the site ofinflammation and measure mediators of airway inflamma-
tion even in severe asthmatics.
The aim of this study was to determine baseline values
of cys-LTs and 8-isoprostane in exhaled breath condensate
of healthy subjects and asthmatic patients. We also inves-
tigated possible correlations between these inflammatory
markers and disease severity.
Methods
Study population
A total of 62 subjects were enrolled in the study and clas-
sified in four groups: 19 healthy non-smokers, 16 mild
asthmatics, 12 moderate asthmatics and 15 patients with
severe asthma. Subjects’ characteristics are summarized in
Table 1. Asthma was defined as clear clinical history with
current symptoms plus 15% reversibility in FEV1 after two
puffs of b2 e agonist and/or positive metacholine chal-
lenge. All patients had physician confirmed diagnosis of
persistent asthma (mild, moderate or severe), according to
GINA guidelines.14 All asthmatic patients were on ICS
therapy at least for 3 months prior to the examination, in
doses according to their asthma severity (see Table 1 with
demographics). None of the patient received anti-leuko-
triene treatment such as montelukast. In moderate asth-
matics add on treatment with LABA and theophylline was
allowed (and in severe asthma oral corticosteroids) and
their dose was stable for at least 2 months prior to their
participation in the study. None of the participants had
upper respiratory tract infection in the previous 4 weeks.
Healthy subjects had no history of asthma or any other
chronic disease, were not receiving any medication and had
normal spirometry. Atopy was assessed by means of skin
prick tests for 18 common aeroallergens (HAL Allergy,
Benelux). Raised total and specific IgE levels (Pharmacia,
Sweden) were also measured.
Study design
The study was cross-sectional. All subjects attended the
Sotiria Chest Hospital Asthma Centre Clinic on one occasion
for clinical examination, spirometry and EBC collection.
Informed and written consent was obtained from all
participating subjects and the protocol was approved by
the Research Ethics Committee of the Hospital and the
National Organization for Medicines.
Pulmonary function testing
Pulmonary function tests were performed on the same day
prior to the measurement of exhaled breath condensate.
Table 1 Patient characteristics.*,@
Control subjects All asthmatics Mild asthma Moderate asthma Severe asthma
Number of patients 19 43 16 12 15
Age, year 47  2.4 49  2.2 44  4.6 50  4.2 54  2.3
Sex, M/F 7/12 14/25 4/8 5/7 5/10
FEV1% predicted 100  2.5 77  3.3 94  3.7y,U 71  3.1x 65  5.4£
Atopy 0 29 12 9 8
BMI 29  0.98 28  0.84 26  0.92 28  1.80 31  1.41
ICS@ 0 415  85 975  130 1850  230
CS p.o. 0 0 0 8
Definition of abbreviation: FEV1Z forced expiratory volume in 1 s.
* Data are expressed as mean  SEM.
y p < 0.001 compared with moderate asthmatics.
U p < 0.001 compared with severe asthmatics.
x p < 0.001 compared with healthy controls.
£ p < 0.001 compared with healthy controls.
@ Beclomethasone equivalent dose.
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capacity (FVC) were measured using a dry spirometer
(Sensor Medics, Vmax22, CA) and the best value of the
three maneuvers was expressed as a percentage of the
predicted value.
Collection of exhaled breath condensate
Exhaled breath condensate was collected in the morning
(ECoScreen, Jaeger, Hoechberg, Germany) according to the
ATS/ERS Task Force recommendations.15 All subjects
breathed in a relaxed manner (tidal breathing) for 10 min
not wearing a noseclip. Approximately 1 mL of breath
condensate was collected in a 2 mL sterile eppendorf tube
and was immediately stored at 80 C for later analysis.
The stability of the frozen samples of EBC for both 8-iso-
prostane and cys-LTs was tested in 12 randomly selected
samples for both patients (8) and controls (4), as previously
described.16 Samples used for stability evaluation were
evenly aliquoted and thawed only once for measurement
performed on the first, fourth and eighth week after
collection (the maximum time between collection and
measurement in any sample).
Measurements of exhaled breath condensate
Exhaled 8-isoprostane concentrations were quantified in
duplicate using a specific enzyme immunoassay kit (Cayman
Chemicals, Ann Arbor, MI) as previously described.17 The
detection limit was 5 pg/mL and the intraassay and inter-
assay variability were  5% and 6%, respectively.
LTC4/D4/E4 concentrations were determined in dupli-
cate using a specific enzyme immunoassay kit (Amersham
Pharmacia Biotech, Amersham, UK), as previously
described.18 The detection limit for this assay was 13 pg/
mL, while the intraassay and interassay variability were
<10%. If cys-LTs were not detected in the breath conden-
sate samples or if they were detected at a concentration
lower than the detection limit, then a value of 13 pg/mL
was arbitrarily assigned to it.
As suggested by recent data,19 we coated all plastic
surfaces with 0.005% Tween 20 for 30 min, to preventabsorbance of fatty acid derivates (eicosanoids and pros-
taglandins) to plastic surfaces.
Statistical analysis
Data concerning subject characteristics are expressed as
means  SEM. Statistical analysis was done using Kruskale
Wallis one way analysis of variance accompanied by Dunn’s
multiple comparison. Spearman’s rank correlation coeffi-
cient was applied to investigate the relation between
different parameters. Uni or multi-variate analysis was
applied whenever needed to adjust for age, gender, atopy
and BMI as potential confounders. A statistical software
package was used for all data analysis and comparisons




The evaluation of the stability of 8-isoprostane in the
frozen EBC samples did not show significant differences
among the three measurements performed (1st week,
[41.4  3 pg/mL], after 4 weeks, [45.2  3 pg/mL] and
after 8 weeks, [46.1  2 pg/mL], pZ 0.19). Similar results
were observed for cys-LTs (1st week, [28.5  1.5 pg/mL],
after 4 weeks, [25.2  1.3 pg/mL] and after 8 weeks,
[26.4  2 pg/mL], pZ 0.1). Individual sample variability
was not significant for both 8-isoprostane and cys-LTs.
8-isoprostane
8-isoprostane levels in breath condensate were detectable
in all healthy subjects (16.4  1.6 pg/mL) and were
increased in patients with asthma (59.3  4.0, p < 0.001).
When compared to healthy controls, 8-isoprostane levels
were significantly increased in mild (49.1  5.2 pg/mL,
p < 0.001), moderate (49.7  5.2 pg/mL, p < 0.001) and
severe asthmatics (77.7  7.3 pg/mL, p < 0.0001). More-
over, 8-isoprostane levels were significantly higher in
Figure 1 8-isoprostane concentration in exhaled breath
condensate of normal subjects and patients with mild,
moderate and severe asthma. Data in all figures are expressed
as mean þ SEM. Mean values are shown by horizontal bars.
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asthma (p < 0.01). There was no significant difference
found in the 8-isoprostane levels of patients with mild and
moderate asthma. Figure 1 shows mean levels of 8-iso-
prostane in patients with mild, moderate and severe
asthma and healthy controls.
Cysteinyl-leukotrienes
Cys-LTs were significantly increased in patients with asthma
(35.5  2.9 pg/mL, p < 0.0001) compared to healthy
controls (17.5  1.2 pg/mL). In seven cases (six controls
and one mild asthmatic) where cys-LT levels were unde-
tectable or lower than the detection limit, a value equal to
the detection limit was arbitrarily assigned to them. When
compared to healthy controls, cys-LT levels were signifi-
cantly higher in patients with moderate (34.6  4.4 pg/mL,
p < 0.05) and severe asthma (47.9  6.0 pg/mL, p < 0.001).
There was no significant difference found between healthy
controls and mild asthmatics (24.4  2.2 pg/mL). Cys-LT
levels were significantly increased in patients with severe
as compared with mild asthma (p < 0.001), while there was
no difference found between moderate and severe asth-
matics. Figure 2 shows mean levels of cys-LTs in healthyFigure 2 Cys-LTs concentration in exhaled breath conden-
sate of normal subjects and patients with mild, moderate and
severe asthma.controls and patients with mild, moderate and severe
asthma.
Correlations
8-isoprostane levels in breath condensate of patients with
asthma strongly correlated with exhaled cys-LT levels
(rZ 0.61, p < 0.0001) (Fig. 3). Subgroup analysis showed
that this correlation persisted only in severe asthmatics
(rZ 0.69, pZ 0.044). 8-isoprostane also weakly correlated
with BMI of asthmatic patients (rZ 0.37, pZ 0.015) and
healthy controls (rZ 0.73, pZ 0.0006) (Fig. 4). Cys-LT
levels inversely correlated with FEV1 (rZ 0.35,
pZ 0.029) (Fig. 5). No correlation was found between
8-isoprostane and FEV1 or between BMI and FEV1.
Discussion
In the present study we evaluated the levels of 8-iso-
prostane and cys-LTs concentration in exhaled breath
condensate. Our study shows that both 8-isoprostane and
cys-LT concentrations in exhaled breath condensate are
significantly higher in patients with asthma than in healthy
adults. Moreover, 8-isoprostane levels were significantly
higher in subjects with severe as compared with mild and
moderate asthma, while there was no significant difference
found between mild and moderate asthmatics. Cys-LT
levels were also significantly higher in patients with
asthma, and more so in moderate and severe asthmatic
patients than in mild asthmatics. These data are confir-
matory to previous studies reporting elevated levels of
these two mediators in patients with asthma. We also found
a significant correlation between 8-isoprostane and cys-LTs
levels in adult asthmatics, which has only been reported in
children with asthma.20,21
A representative group of patients with persistent
asthma according to GINA, matched for gender and age was
carefully selected. All patients received treatment
according to their asthma severity. All recommendations by
the ATS/ERS Task Force15 were applied during the collec-
tion procedure of exhaled breath condensate and all
samples were analyzed within 2 months of collection andFigure 3 Correlation between cys-LTs and 8-isoprostane
concentrations in exhaled breath condensate of subjects with
asthma.
Figure 4 Correlation between 8-isoprostane concentration
and BMI in exhaled breath condensate of healthy controls and
subjects with asthma.
754 K. Samitas et al.were measured in duplicates to decrease the possibility of
error.
Inflammation and oxidative stress are cardinal features
of asthma. Quantification of oxidant stress status can take
place by either directly measuring free radicals or by
measuring stable byproducts of lipid peroxidation. Several
in vitro biomarkers of oxidative stress are available;
regrettably most of them are of limited value in vivo
because they either lack sensitivity and/or specificity, or
require invasive methods.22 8-isoprostane is a specific,
stable product of lipid peroxidation that is formed in vivo by
ROS peroxidation of arachidonic acid.5 It is present in
detectable amounts in all normal tissues and biological
fluids,10e13 thus allowing definition of normal ranges, and is
unaffected by the lipid content of the diet.23 8-isoprostane
is considered an ideal marker for investigating oxidative
injury in asthma.24
Previous studies have indicated increased 8-isoprostane
levels of both systemic15 and airway concentrations25 of
adults with asthma. We have demonstrated that 8-iso-
prostane concentration in EBC was higher in adult asth-
matic patients than in healthy control subjects, indicating
that lipid peroxidation and oxidative stress are increased in
the lungs of patients with asthma. Other authors reportedFigure 5 Correlation between cys-LTs concentration in
exhaled breath condensate of subjects with asthma and FEV1%
predicted.a similar increase in 8-isoprostane in EBC of patients with
stable moderate asthma who were either steroid-naı¨ve or
treated with ICS.26 Montuschi et al.27 have also demon-
strated a comparable increase of 8-isoprostane in EBC of
asthmatic patients. In keeping with this study, we have
shown that 8-isoprostane EBC levels increase with disease
severity. We also found that in patients with mild and
moderate asthma 8-isoprostane levels were almost tripled
compared to healthy controls, while severe asthmatics
exhibited approximately a 4-fold increase. Subjects with
moderate asthma had levels of 8-isoprostane comparable to
those observed in subjects with mild asthma, which could
be attributed to a controlling effect of ICS, up to a certain
extent, in these patients. However, conflicting data have
been reported on the effects of corticosteroids on 8-iso-
prostane; in children with asthma who were either steroid-
naı¨ve or treated with ICS, 8-isoprostane EBC levels were
elevated compared to those in healthy children, but there
was no difference between the two study groups.28e30 In
our study, severe asthmatics had significantly higher 8-iso-
prostane levels compared to both mild and moderate
asthmatics, despite treatment with oral and/or high doses
of ICS.
Cys-LTs have been implicated in asthma pathophysi-
ology.31 Increased LTC4 levels were reported in BAL,10
induced sputum;32 and EBC of asthmatics. We showed that
cys-LT levels in EBC of asthmatic patients are elevated
compared to healthy subjects. Our findings are consistent
with the results of previous studies reporting increased cys-
LTs EBC concentrations in patients with asthma.18,33,34 In
keeping with Hanazawa et al.,18 we have demonstrated
that EBC cys-LT levels are significantly higher in patients
with moderate and severe asthma than in subjects with
mild asthma and control subjects, although we found no
difference between healthy controls and mild asthmatics.
This suggests that, compared to mild asthmatics or healthy
controls, patients with moderate and severe asthma has
increased baseline production of cys-LTs.
In our study there was a significant correlation between
exhaled 8-isoprostane and cys-LT levels in breath conden-
sate of patients with asthma. After performing a subgroup
analysis, we found that this correlation persisted only in the
severe asthmatics group. Although cys-LTs and 8-iso-
prostane are thought to reflect different aspects of airway
inflammation and their levels could increase independently
of each other, this correlation maybe indicative of a link
between inflammation and oxidative stress in the airways
of patients with asthma. This association seems to be even
more prominent in patients with severe asthma, where
inflammation and oxidative stress levels are more
pronounced. Similar data have been reported in children;
Baraldi and coworkers20 found a significant correlation
between 8-isoprostane and cys-LTs in ICS-treated asthmatic
children that did not persist after oral treatment with
prednisone, suggesting that steroids may affect iso-
prostanes and leukotrienes differently. Zanconato and
coworkers21 also reported a significant correlation between
8-isoprostane and cys-LTs in EBC of ICS-treated children
with stable asthma. In addition, we found a small but
significant negative association between cys-LT EBC levels
and FEV1, which could be explained by the bronchocon-
strictive effect of cys-LTs.8 Bronchoconstriction per se
Exhaled eicosanoids in asthma and their relation to clinical severity 755might influence indirectly the concentrations of EBC
molecules due to factors such as drying of mucosal
membranes, higher viscosity of airway fluid, collection of
solutes from more proximal airways, especially in severe
asthmatics where bronchoconstriction is more prominent.
This could be an alternative explanation of the correlation
found between FEV1 and cys-LT, other than the broncho-
constrictive effect of cys-LT.
We have also found a significant correlation between
8-isoprostane and BMI in both asthmatic patients and
healthy controls. Similar results have been reported
recently,35 although this association was not observed in
healthy non-asthmatics. Our finding that BMI is associated
with higher EBC levels of 8-isoprostane (but not cys-LTs) in
both healthy subjects and asthmatics may be attributed to
a parallel increase in baseline airway oxidative stress and/
or to obesity-related changes in the production of adipo-
kines.35 Since the association of BMI with 8-isoprostane EBC
levels could affect our results, all presented data on 8-
isoprostane have been adjusted for BMI as a confounder.
Our study presents certain limitations. In an observa-
tional cross-sectional study it is very difficult to determine
causation and specific mechanisms of action. In addition,
although EBC analysis based on recent guidelines15 is widely
used for investigating airway pathology, it is still not a fully
standardized method.36,37 Another limitation of the present
study is that a reference dilution indicator was not used.
The high inter-individual variability in the amount of
aerosol particles in EBC indicates the need for a dilution
marker.13 Finally, we could have concentrated our samples
as suggested19 to avoid undetectable levels of cys-LTs in
EBC of some healthy controls and mild asthmatics.
In conclusion, we have shown that 8-isoprostane and
cys-LTs are detectable in breath condensate of healthy
subjects and that their levels progressively increase in
patients with asthma according to disease severity. This
study shows that EBC may be an effective tool in assessing
airway inflammation and oxidative stress status in patients
with asthma.
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